Real-Life Tolerability and Effectiveness of Adalimumab Biosimilar in Rheumatoid Arthritis: ASPIRE Registry Data
Abstract Introduction The TNF-α blocker adalimumab is a well-proven therapy for rheumatoid arthritis (RA). A biosimilar adalimumab (ZRC-3197; Exemptia™), a ‘fingerprint match’ to reference adalimumab, has been approved for prescription in India since 2014. Here, we report on the effectiveness and to...
| 主要な著者: | , , , , |
|---|---|
| フォーマット: | 論文 |
| 言語: | English |
| 出版事項: |
Adis, Springer Healthcare
2019-06-01
|
| シリーズ: | Rheumatology and Therapy |
| 主題: | |
| オンライン･アクセス: | http://link.springer.com/article/10.1007/s40744-019-0166-2 |